Hipertension y Riesgo Vascular最新文献

Real-world efficacy and safety of baroreceptor activation therapy in a series of patients with refractory arterial hypertension [压力感受器激活疗法在一系列难治性高血压患者中的实际疗效和安全性]。

IF 1.2

Hipertension y Riesgo Vascular Pub Date : 2025-04-01 DOI: 10.1016/j.hipert.2024.10.004

A. Bustos-Merlo , D. Rico-López , F. Jaén-Águila , C. López-Espada , M.I. Rodríguez-Macías , J.D. Mediavilla-García

{"title":"Real-world efficacy and safety of baroreceptor activation therapy in a series of patients with refractory arterial hypertension","authors":"A. Bustos-Merlo , D. Rico-López , F. Jaén-Águila , C. López-Espada , M.I. Rodríguez-Macías , J.D. Mediavilla-García","doi":"10.1016/j.hipert.2024.10.004","DOIUrl":"10.1016/j.hipert.2024.10.004","url":null,"abstract":"<div><div>The number of patients suffering from refractory hypertension and advanced-stage chronic heart failure (CHF) is progressively increasing. In recent years, device-mediated therapies have been developed as an alternative or adjunct to conventional medical treatment. Our primary objective is to describe the clinical experience in a series of patients with refractory hypertension following the implantation of baroreceptor activation therapy (BAT). We analyzed five patients with refractory hypertension, one of whom also had CHF, treated in a specialized cardiovascular risk clinic. After the implantation of the Barostim device with an average activation of 3.64mA (ranging from 2.80 to 5.4), there was a mean reduction of 30±7.68mmHg (<em>p</em>     =0.03) in systolic and diastolic blood pressure, respectively, as measured by ambulatory blood pressure monitoring (ABPM), along with a heart rate reduction of 25±9.13bpm (<em>p</em>  <!-->0.004). A reduction in the number of antihypertensive medications required for blood pressure control was observed, with an average of 5.2 medications, as well as an improvement in functional class. No adverse events were recorded in our patient series. Currently, BAT is considered a compassionate-use alternative for blood pressure control in patients with refractory hypertension and failure of pharmacological treatment and other invasive techniques, such as renal denervation.</div></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"42 2","pages":"Pages 67-71"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of the effectiveness of aliskiren and ramipril for the management of hypertension: A systematic review and meta-analysis 阿利克伦和雷米普利治疗高血压的疗效比较：一项系统回顾和荟萃分析。

IF 1.2

Hipertension y Riesgo Vascular Pub Date : 2025-04-01 DOI: 10.1016/j.hipert.2024.11.002

T. Alam , M. Asif Ansari

{"title":"Comparison of the effectiveness of aliskiren and ramipril for the management of hypertension: A systematic review and meta-analysis","authors":"T. Alam , M. Asif Ansari","doi":"10.1016/j.hipert.2024.11.002","DOIUrl":"10.1016/j.hipert.2024.11.002","url":null,"abstract":"<div><h3>Objective</h3><div>Ramipril is an important option in the management of hypertension, while the role of aliskiren is still up for debate. We aim to meta-analyse and compare the effect of aliskiren with ramipril by measuring mean difference in systolic blood pressure (mdSBP) and mean difference in diastolic blood pressure (mdDBP).</div></div><div><h3>Methods</h3><div>The search was conducted using the PubMed and Cochrane databases for eligible randomized clinical trials (RCTs) to perform a meta-analysis from January 2000 to May 2024. RCTs that included hypertensive patients who were under either aliskiren or ramipril treatment were included in the analysis. The risk of bias was evaluated using RoB 2.0. This study is registered with PROSPERO: CRD42024577105.</div></div><div><h3>Results</h3><div>Four studies were included: two studies were carried out for 2 months, and two were carried out for 6 months, including 693 and 329 patients, respectively, with mild to moderate hypertension and a mean age of 55.2 years. After 2 months, mdDBP was found to be significant (mdDBP=0.85mmHg, 95% CI: 0.73–0.97, <em>I</em><sup>2</sup>     =0%). There was a significant difference in the mdSBP (mdSBP=3.15mmHg, 95% CI: 2.13–4.17, <em>I</em><sup>2</sup>     =0%) at 6 months.</div></div><div><h3>Conclusion</h3><div>Aliskiren provides, in the short term, a slight improvement in BP in non-elderly hypertensive patients without diabetes or previous cardio-cerebrovascular disease.</div></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"42 2","pages":"Pages 94-101"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hypertension and uric acid, uric acid and hypertension: Is hyperuricaemia a new vascular risk factor to take into account? 高血压与尿酸，尿酸与高血压：高尿酸血症是需要考虑的新血管风险因素吗？

IF 1.2

Hipertension y Riesgo Vascular Pub Date : 2025-04-01 DOI: 10.1016/j.hipert.2024.12.001

M. Benitez Camps

引用次数: 0

Association of different domains of sedentary behavior and cardiovascular risk factors in adolescents: Cross-sectional study 青少年不同领域的久坐行为与心血管风险因素的关系：横断面研究

IF 1.2

Hipertension y Riesgo Vascular Pub Date : 2025-04-01 DOI: 10.1016/j.hipert.2024.10.002

E.P. Antunes , W.R. Tebar , G.G. Cucato , C.C.M. Silva , I. Leoci , A.B. dos Santos , G. Ferrari , D.G.D. Christofaro

{"title":"Association of different domains of sedentary behavior and cardiovascular risk factors in adolescents: Cross-sectional study","authors":"E.P. Antunes , W.R. Tebar , G.G. Cucato , C.C.M. Silva , I. Leoci , A.B. dos Santos , G. Ferrari , D.G.D. Christofaro","doi":"10.1016/j.hipert.2024.10.002","DOIUrl":"10.1016/j.hipert.2024.10.002","url":null,"abstract":"<div><h3>Background</h3><div>Sedentary behavior (SB) has been related to cardiovascular risk factors (CVRF) such as high BMI, waist circumference (WC) and blood pressure (BP), including pediatric populations. However, it is still unclear whether the association between SB and CVRF could be domain dependent. Therefore, this study aimed to analyze the relationship between sedentary at different domains (time spent in TV, videogames, computer, smartphone) with CVRF in adolescents.</div></div><div><h3>Methods</h3><div>A sample of 1011 adolescents (10–17 years old; 55.1% girls) was assessed. The different BS domains were obtained through a questionnaire, as well as socioeconomic status, habitual physical activity, smoking and alcohol consumption. BMI was calculated by objectively measured height and body mass, WC was assessed at middle point between the last rib and iliac crest, and BP was assessed by a digital oscillometric device. The relationship between SB and CVRF was determined by quantile regression, adjusted for sex, age, socioeconomic status, physical activity, smoking and alcohol consumption.</div></div><div><h3>Results</h3><div>Elevated time in smartphone use was associated with higher median values of WC (<em>β</em>  =2.70; 95%CI: 0.35; 5.05). High total time spent in SB was associated with higher median values of BMI (<em>β</em>    =1.95; 95%=0.47; 3.42) and SBP (<em>β</em>  <!-->2.52; 95%CI: 0.37; 4.68).</div></div><div><h3>Conclusions</h3><div>Smartphone use and total SB time were related to higher CVRF in adolescents. Cardiovascular health promotion strategies should focus on reducing SB in pediatric populations, especially smartphone use.</div></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"42 2","pages":"Pages 72-78"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142733131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Refractory arterial hypertension. What can we offer these patients? 难治性动脉高血压。我们能为这些病人提供什么？

IF 1.2

Hipertension y Riesgo Vascular Pub Date : 2025-04-01 DOI: 10.1016/j.hipert.2024.12.004

J. Segura , P. Armario

引用次数: 0

The complex interplay: How lifestyle and psychosocial factors contribute to hypertension in myocardial infarction patients—An integrated model 复杂的相互作用：生活方式和社会心理因素如何导致心肌梗死患者的高血压--一个综合模型。

IF 1.2

Hipertension y Riesgo Vascular Pub Date : 2025-04-01 DOI: 10.1016/j.hipert.2024.11.001

H. Roohafza , M. Mansourian , F. Zarimeidani , R. Rahmati , N. Shakibaei , H. Marateb , F. Noohi , A. Salari , M. Sadeghi

{"title":"The complex interplay: How lifestyle and psychosocial factors contribute to hypertension in myocardial infarction patients—An integrated model","authors":"H. Roohafza , M. Mansourian , F. Zarimeidani , R. Rahmati , N. Shakibaei , H. Marateb , F. Noohi , A. Salari , M. Sadeghi","doi":"10.1016/j.hipert.2024.11.001","DOIUrl":"10.1016/j.hipert.2024.11.001","url":null,"abstract":"<div><h3>Introduction</h3><div>A significant proportion of acute myocardial infarction (MI) patients also suffer from hypertension (HTN), underscoring the need for effective HTN prevention and management strategies in this group. This study aims to elucidate the complex web of direct and indirect factors contributing to HTN in the context of MI.</div></div><div><h3>Material and methods</h3><div>The study utilized longitudinal data from patients aged 18–75 experiencing their first ST-segment elevation MI from five major provinces of Iran, including Tehran, Isfahan, Yazd, Gilan, and Hormozgan. HTN was the primary endpoint, with contributing factors including lifestyle, psychological factors, socioeconomic status, and comorbidities. We applied Bayesian structural equation modeling to analyze the interplay among 14 key variables influencing HTN in MI patients.</div></div><div><h3>Results</h3><div>Among the 1699 participants, 424 men (69.9%) and 181 women (30.1%) were identified as having HTN. Our multi-dimensional analysis revealed that increased comorbidities directly escalate blood pressure levels. Furthermore, the adoption of a healthier lifestyle characterized by sufficient physical activity, quality sleep, sexual satisfaction, non-smoking status, and a favorable dietary score, along with the enhancement of psychosocial factors such as stress management and the modification of type D personality traits and socioeconomic status can curb HTN directly and indirectly.</div></div><div><h3>Conclusion</h3><div>This study integrates diverse factors into a multi-dimensional model and offers insights into new preventive avenues for HTN in MI patients. Our findings can inform strategies to mitigate HTN risk in this vulnerable population by pinpointing both direct and indirect predictors and intervention points.</div></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"42 2","pages":"Pages 85-93"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143532035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physicians’ perception of guideline recommendations for the treatment of resistant hypertension by renal denervation: Resistant Hypertension Working Group, Argentine Hypertension Society 医生对肾去神经支配治疗顽固性高血压的指南建议的看法：阿根廷高血压学会顽固性高血压工作组。

IF 1.2

Hipertension y Riesgo Vascular Pub Date : 2025-04-01 DOI: 10.1016/j.hipert.2024.10.003

N.F. Renna , L. Brandani , R. Parodi , C. Kotliar , E. Ylarri , G. Lavenia , M. Marin , M. Ruise , R. Sanchez , D. Cianfagna , G. Botvinik , P. Rumi , V. Ferreti , P. Rodríguez

{"title":"Physicians’ perception of guideline recommendations for the treatment of resistant hypertension by renal denervation: Resistant Hypertension Working Group, Argentine Hypertension Society","authors":"N.F. Renna , L. Brandani , R. Parodi , C. Kotliar , E. Ylarri , G. Lavenia , M. Marin , M. Ruise , R. Sanchez , D. Cianfagna , G. Botvinik , P. Rumi , V. Ferreti , P. Rodríguez","doi":"10.1016/j.hipert.2024.10.003","DOIUrl":"10.1016/j.hipert.2024.10.003","url":null,"abstract":"<div><h3>Introduction</h3><div>This study investigates the perceptions and knowledge of specialized Argentine physicians regarding renal denervation (RDN) as a treatment for resistant hypertension (R-HT).</div></div><div><h3>Method</h3><div>A survey was conducted among 206 physicians, mainly cardiologists and internists, to assess their awareness and perceptions of RDN. Data were analyzed using descriptive statistics and Spearman's Rho correlation.</div></div><div><h3>Results</h3><div>The survey revealed that 83% of the responders are aware of RDN. Despite this high awareness, only 60% believe in its safety, while 33.2% are uncertain, and 6.8% consider it unsafe. Significant correlations were found between the awareness of RDN and perceptions of its efficacy and safety.</div></div><div><h3>Conclusions</h3><div>The study highlights a gap between knowledge and confidence in RDN among specialized Argentine physicians. Continuous education and shared decision-making are crucial to improve the adoption of RDN in clinical practice. Long-term safety and efficacy data support RDN as a valuable tool for managing R-HT. Addressing safety concerns through targeted educational initiatives is essential.</div></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"42 2","pages":"Pages 79-84"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cutting-edge lipid-lowering pharmacological therapies: Improving lipid control beyond statins 尖端降脂药物疗法：改善血脂控制超越他汀类药物

IF 1.2

Hipertension y Riesgo Vascular Pub Date : 2025-04-01 DOI: 10.1016/j.hipert.2024.12.002

M. Capuozzo , A. Ottaiano , C. Cinque , S. Farace , F. Ferrara

{"title":"Cutting-edge lipid-lowering pharmacological therapies: Improving lipid control beyond statins","authors":"M. Capuozzo , A. Ottaiano , C. Cinque , S. Farace , F. Ferrara","doi":"10.1016/j.hipert.2024.12.002","DOIUrl":"10.1016/j.hipert.2024.12.002","url":null,"abstract":"<div><div>Statins are crucial for both the prevention and management of atherosclerotic cardiovascular disease (ASCVD). However, even with optimized statin therapy, a significant residual risk of ASCVD remains, highlighting the need for innovative approaches to lipid-lowering therapies (LLT) that more effectively target low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipoproteins. Recently, novel pharmacologic agents have been introduced for the management of dyslipidemia. Bempedoic acid, an inhibitor of ATP citrate lyase, has emerged as a promising alternative for patients who exhibit statin intolerance. Moreover, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have transformed the management of hypercholesterolemia by reducing LDL-C levels. PCSK9 is a protein that mediates LDL receptor degradation; its inhibition enhances LDL receptor recycling, facilitating increased LDL-C uptake. New antisense oligonucleotides targeting apolipoprotein C3 (apoC3), ANGPTL3, and lipoprotein(a) have demonstrated significant reductions in these molecules, offering potential therapeutic advantages for certain dyslipidemias. Ongoing research is also evaluating apolipoprotein A1 (apoA1) to leverage the protective effects of high-density lipoprotein cholesterol (HDL-C), though conclusive clinical evidence is still required. This review examines the mechanisms and clinical efficacy of emerging LLT other than statins, focusing on bempedoic acid and PCSK9 inhibitors. Bempedoic acid acts upstream in the cholesterol biosynthesis pathway, offering a potentially safer option for patients intolerant to statins. PCSK9 inhibitors enhance LDL receptor recycling, significantly lowering LDL-C levels and reducing cardiovascular risk. A deeper understanding of these mechanisms is essential for the advancement of therapeutic strategies in dyslipidemia and cardiovascular disease management.</div></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"42 2","pages":"Pages 116-127"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144364361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Position statement on the use of amlodipine during pregnancy. Working Group on Hypertension in Women, Argentine Society of Hypertension [妊娠期间使用氨氯地平的立场声明。]阿根廷高血压学会妇女高血压工作组]。

IF 1.2

Hipertension y Riesgo Vascular Pub Date : 2025-04-01 DOI: 10.1016/j.hipert.2024.11.004

A.M. Ghelfi , G. Miranda , L.S. Voto , M.A. Del Sueldo , J.M. Zilberman , R. Mondino , M.P. Pérez , P.G. Irusta , L. Meccia , E. Martínez Marissi , M. Laura Baiche , F. Waisman , M. BaronI , M. Victoria FerrettI , J.P. Morán , A. Corrales Barboza , A.M. Delucchi , P.D. Rodríguez , N.F. Renna

{"title":"Position statement on the use of amlodipine during pregnancy. Working Group on Hypertension in Women, Argentine Society of Hypertension","authors":"A.M. Ghelfi , G. Miranda , L.S. Voto , M.A. Del Sueldo , J.M. Zilberman , R. Mondino , M.P. Pérez , P.G. Irusta , L. Meccia , E. Martínez Marissi , M. Laura Baiche , F. Waisman , M. BaronI , M. Victoria FerrettI , J.P. Morán , A. Corrales Barboza , A.M. Delucchi , P.D. Rodríguez , N.F. Renna","doi":"10.1016/j.hipert.2024.11.004","DOIUrl":"10.1016/j.hipert.2024.11.004","url":null,"abstract":"<div><div>Pharmacological management of HDP includes agents supported by extensive evidence ensuring their safety for use. Among those traditionally described in the literature are: alpha-methyldopa, labetalol, and sustained-release nifedipine (NIF-RETARD). These drugs, in addition to being compatible with pregnancy, present additional eligibility criteria.</div><div>The discontinuation of NIF-RETARD has resulted in the off-label use of other dihydropyridine calcium cannel blockers with lower levels of evidence in pregnancy, such as amlodipine.</div><div>The Working Group Hypertension in Women of the Argentine Society of Hypertension has proposed to develop a document that precisely and thoroughly addresses the concerns related to the use of amlodipine in pregnancy, providing responses based on the currently available scientific evidence.</div></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"42 2","pages":"Pages 102-107"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Positioning for the use of multivessel clinical ultrasound in vascular risk evaluation: VASUS+ protocol. 2024 recommendations of the Vascular Risk Group, clinical ultrasound of the Spanish Society of Internal Medicine and Spanish Society of Hypertension and Vascular Risk 多血管临床超声在血管风险评估中的定位：VASUS+方案。血管风险组2024年建议，西班牙内科学会和西班牙高血压和血管风险学会的临床超声。

IF 1.2

Hipertension y Riesgo Vascular Pub Date : 2025-04-01 DOI: 10.1016/j.hipert.2024.11.003

E. Moya Mateo , R. García Alonso , C. Sánchez Sánchez , Y. Tung-Chen , E. Rodilla , L. Beltrán Romero , J.A. García-Donaire , M.V. Bonilla-Hernández , N. Muñoz-Rivas , L. Castilla-Guerra

{"title":"Positioning for the use of multivessel clinical ultrasound in vascular risk evaluation: VASUS+ protocol. 2024 recommendations of the Vascular Risk Group, clinical ultrasound of the Spanish Society of Internal Medicine and Spanish Society of Hypertension and Vascular Risk","authors":"E. Moya Mateo , R. García Alonso , C. Sánchez Sánchez , Y. Tung-Chen , E. Rodilla , L. Beltrán Romero , J.A. García-Donaire , M.V. Bonilla-Hernández , N. Muñoz-Rivas , L. Castilla-Guerra","doi":"10.1016/j.hipert.2024.11.003","DOIUrl":"10.1016/j.hipert.2024.11.003","url":null,"abstract":"<div><div>Atherosclerosis is the underlying disease in the entire spectrum of atherosclerotic vascular disease. Point of care ultrasound is a useful tool for its detection. Current guidelines recommend the use of scales such as SCORE 2 and SCORE 2OP in apparently healthy individuals and in those at intermediate-low risk, they recognize the role of the arterial plaque by ultrasound to refine risk stratification and the need for more aggressive preventive strategies. However, the way to evaluate the vascular territories in which there is presence of plaque, the amount or load of plaque is not homogeneous nor is it well protocolized. In this document, 2 protocols are proposed for the evaluation of vascular risk, VASUS and VASUS+, including the presence of ventricular hypertrophy with the objective of homogenizing clinical ultrasound in the assessment of vascular risk in clinical practice.</div></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"42 2","pages":"Pages 108-115"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0